Decision models in type 2 diabetes mellitus: A systematic review

Jiayu Li1,2,3 · Yun Bao2 · Xuedi Chen1,2 · Limin Tian1,2

Received: 27 February 2021 / Accepted: 7 May 2021 / Published online: 3 June 2021 © The Author(s) 2021

Abstract
Aims To reduce the burden of type 2 diabetes (T2DM), the disease decision model plays a vital role in supporting decision-making. Currently, there is no comprehensive summary and assessment of the existing decision models for T2DM. The objective of this review is to provide an overview of the characteristics and capabilities of published decision models for T2DM. We also discuss which models are suitable for different study demands.

Materials and methods Four databases (PubMed, Web of Science, Embase, and the Cochrane Library) were electronically searched for papers published from inception to August 2020. Search terms were: “Diabetes-Mellitus, Type 2”, “cost-utility”, “quality-of-life”, and “decision model”. Reference lists of the included studies were manually searched. Two reviewers independently screened the titles and abstracts following the inclusion and exclusion criteria. If there was insufficient information to include or exclude a study, then a full-text version was sought. The extracted information included basic information, study details, population characteristics, basic modeling methodologies, model structure, and data inputs for the included applications, model outcomes, model validation, and uncertainty.

Results Fourteen unique decision models for T2DM were identified. Markov chains and risk equations were utilized by four and three models, respectively. Three models utilized both. Except for the Archimedes model, all other models (n = 13) implemented an annual cycle length. The time horizon of most models was flexible. Fourteen models had differences in the division of health states. Ten models emphasized macrovascular and microvascular complications. Six models included adverse events. Majority of the models (n = 11) were patient-level simulation models. Eleven models simulated annual changes in risk factors (body mass index, glycemia, HbA1c, blood pressure (systolic and/or diastolic), and lipids (total cholesterol and/or high-density lipoprotein)). All models reported the main data sources used to develop health states of complications. Most models (n = 11) could deal with the uncertainty of models, which were described in varying levels of detail in the primary studies. Eleven studies reported that one or more validation checks were performed.

Conclusions The existing decision models for T2DM are heterogeneous in terms of the level of detail in the classification of health states. Thus, more attention should be focused on balancing the desired level of complexity against the required level of transparency in the development of T2DM decision models.

Keywords Type 2 diabetes mellitus · Decision model · Simulation · Cost-utility

Introduction
Diabetes is a major health issue that has reached alarming levels. Today, nearly half a billion people are living with diabetes worldwide. In 2017, it was estimated that 425 million people had diabetes (types 1 and 2 combined), increasing to 463 million in 2019, and this number is projected to reach 578 million by 2030 [1]. Due to population growth and aging, the Global Burden of Disease Study showed that all-age disability-adjusted life-years (DALYs) of people with diabetes in 2016 were 57,233.7, which increased by 24.4% from 1990 to 2016 [2]. To decrease the high disease
burden [3–5], efficient prevention and treatment of diabetes and its complications are major tasks for health policy. In these situations, disease decision models play a vital role in supporting decision-making for evaluating the long-term health and economic outcomes of interventions in the public and private health sectors [6].

Disease decision models are logical mathematical frameworks that synthesize the available data (e.g., short-run clinical trial outcomes, risk equations, and progression rates) and known physiologic relationships into a coherent internally consistent framework that can be extrapolated over time [7, 8]. Many models have been developed and validated for type 2 diabetes mellitus (T2DM) populations and used in a variety of ways, such as estimating long-term clinical outcomes and costs of a clinical trial and aiding decision makers in choosing between available interventions in these populations [9–12]. For instance, the Centers for Disease Control (CDC) Diabetes Cost-effectiveness Group used the Diabetes Cost-Effectiveness Model (DCEM) to estimate the incremental cost-effectiveness of intensive glycemic control (relative to conventional control), intensified hypertension control, and reduction in serum cholesterol levels in patients with T2DM [12]. From a modeling standpoint, T2DM ranks among the most challenging disease areas because of its impact on multiple interrelated organ systems and multiple treatment goals (including blood glucose, blood pressure, and blood lipids) [13]. However, unlike models in type 1 diabetes mellitus (T1DM) and prediabetes [14, 15], there are few comprehensive summaries and assessments of the existing decision models for T2DM.

Our research provides an overview of the characteristics and capabilities of published decision models in T2DM. We also discuss which models are more suitable for different study demands.

Methods

Search strategy and selection criteria

This systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [16].

Four databases (PubMed, Web of Science, Embase, and the Cochrane Library) were electronically searched for papers that were published from inception to August 2020. The following search terms/MeSH terms were used: “Diabetes Mellitus”, “Type 2”, “cost-utility”, “quality of life”, and “decision model”. The integral search strategy is provided in Appendix 1. We also manually searched the reference lists of the included studies. References were managed using ENDNOTE X9 (Clarivate, Philadelphia, PA). Studies were eligible for inclusion if they met the following predefined criteria:

1. Population: Patients with T2DM; modeling studies conducted in a mixed population (T1DM and T2DM) were included only if the model adaptation for T2DM patients was reported separately in the full-text publication;
2. Intervention and comparators: No restrictions;
3. Outcomes: Studies with decision models in T2DM that reported health economics outcomes such as costs, (quality-adjusted) life expectancy, and diabetes-related complications;
4. Study design: All modeling studies capable of performing a full economic evaluation were included.

The exclusion criteria were as follows:

1. Population: T1DM only, or gestational diabetes or maturity-onset diabetes of the young (MODY);
2. Outcomes: Modeling studies with a limited focus on particular sub-components of T2DM (e.g., only one complication of T2DM), or modeling application studies with a time horizon of ≤ 5 years;
3. Study design: Abstracts or full-text unavailable.

Two reviewers (L.J. and C.X) independently screened the titles and abstracts according to the inclusion criteria. If there was insufficient information to include or exclude a study, then a full-text version was sought. A consensus between both reviewers was required. Full-text versions of all the relevant studies were also obtained and read by two independent reviewers (L.J. and B.Y.) to ensure that the inclusion criteria were met. Any disagreement between the two reviewers was resolved by a third reviewer for assessment. If there was insufficient information to include a study, then the authors were contacted when possible.

Quality assessment

Two reviewers (L.J. and B.Y.) independently assessed the quality of all the included studies by using the Philips et al. [17] checklist, which assesses the quality of reporting of the decision models and model-based economic evaluations, as recommended in the Cochrane Handbook for Systematic Reviews of Interventions [18]. Any disagreement between the two reviewers was resolved by a third reviewer for the assessment. The checklist by Philips et al. evaluates three domains of a model: (1) structure, (2) data, and (3) consistency.
Data extraction and analysis

If a decision model was found to be associated with multiple studies, these studies were assessed as sharing the same parent model: Only the primary study (the study that described the model in greater detail) for each model was considered for the review, while supplementary and subsequent studies were documented as secondary studies. Data from secondary studies were not extracted. Data from the identified studies included in the review were extracted into data extraction grids (supplementary material Appendix 2) by two independent reviewers (L.J. and B.Y.). The extracted information included basic information, study details, population characteristics, basic modeling methodologies, model structure, data inputs for the included applications, model outcomes, model validation, and uncertainty.

Results

A total of 25,995 related studies were searched in this systematic review; 10,102 duplicates were removed, and 15,893 studies were excluded based on first-pass screening using the title and abstract. Following the full-text review, 140 identified studies involving 14 decision models in T2DM were identified. Figure 1 shows the flow of studies throughout the review. Among the 140 identified studies, 79 used the CORE Diabetes Model (CDM), 17 used the Cardiff model, 14 used the...
Eleven identified models were patient-level simulation models, while cohorts were used in the DCEM and IHE models. Either the patient-or cohort-level simulation method can be used in the CDM model. Except for the Archimedes model and the ECHO model, others illustrated the model perspective in the primary citations. Ten models considered a healthcare-related perspective in the base case (7 models [9–12, 21, 26, 28] used a healthcare-system perspective, 2 models [23, 25] used a healthcare-decision-maker perspective, and 1 model [27] used a healthcare-payer perspective), while the NIDDM and Sheffield models considered a patient perspective and a social perspective, respectively.

Thirteen models used an annual cycle length, while the Archimedes model was continuous in time. Three models [21, 26, 27] did not use an annual cycle length for specific health states. The time horizon of 9 models [9–11, 19, 20, 23–25, 27] was defined by users, up to one’s lifetime, while the time horizon of 5 models [12, 21, 22, 26, 28] was set to one’s lifetime. The transition probabilities between models varied in complexity. Risk equations were applied in most models to handle transition probabilities depending on the epidemiology of T2DM, the risk factors, the incidence and prevalence of diabetic complications, and comorbidities.

### Incorporation of risk factors

Eleven models [10, 11, 20–28] simulated annual changes in risk factors such as body mass index (BMI), glycemia, HbA1c, blood pressure (systolic and/or diastolic), and lipids (total cholesterol and/or high-density lipoprotein) (Table 2). The simulated trajectory of risk factors could affect the subsequent occurrence or development of diabetes and its complications. The DCEM and COMT models precisely controlled risk factors to reduce the onset and development of diabetes and its complications.

### Model outcomes

The major model outcomes are summarized as follows (Table 5):

Twelve models [11, 12, 19–28] reported life-years (LYs), ten model [11, 12, 19, 20, 22–27] reported incremental cost-effectiveness ratios (ICERs), and thirteen models [10–12, 19–28] reported quality-adjusted life years (QALYs). The ECHO and IHE models also reported net monetary benefits (NBMs). Some models [9, 10, 12, 19, 22, 24, 26, 27] also reported other outcomes.

---

**Model structure**

Tables 1 and 2 show aspects of model structures. Eight model structures [10–12, 22, 23, 25, 26, 28] were constructed in reference to pre-existing models. Models had certain differences in how health states were divided (Tables 3 and 4). The DCEM model placed greater emphasis on macrovascular complications, whereas the NIDDM and Michigan models placed greater emphasis on microvascular complications. Other models, apart from the Archimedes model, emphasized both macrovascular and microvascular complications (CDM, UKPDS OM1/2, IHE, ODEM, Cardiff, Sheffield, CDS, COMT, ECHO). The Archimedes model has no clear-cut health states, as it is continuous in time, with no discrete time steps, and any event could occur at any time. The IHE model included numerous health states for complications and used two parallel Markov chains. The first chain consisted of 120 different microvascular health states, and the second chain was made up of 100 different macrovascular health states. Six models [19, 22–24, 26, 27] included adverse events. Almost all these models classified them as treatment outcomes, not as independent health states. However, the CDM model incorporated adverse events into the model as independent health states. All models included death as a health state, while each model had different levels of detail in this state.
All models reported costs, albeit at different levels of detail. Eleven models \([9, 11, 12, 19, 20, 22–27]\) reported direct costs, whereas the CDM and IHE models reported both direct and indirect costs. Three models (UKPDS OM1/2 and the Michigan model) did not describe cost in detail. The outcomes of three models (UKPDS OM1/2 model and the Michigan model) included costs, but none of the included studies classified costs into direct and indirect costs.

### Health utility

All models reported utility values as outcomes. Thus, subsequent cost-utility analyses (CUA) could be performed. Each health state in a model had a corresponding utility value.
| Model Name | Intervention and comparator | Basic data entered | Risk factors (base case) | Discounting | Model outcomes |
|-----------|-----------------------------|--------------------|--------------------------|-------------|----------------|
| NIDDM [20] | NR                          | Age, sex, ethnicity, age at diagnosis of diabetes | Age, BMI, smoking, race, cholesterol, BP, income, physical activity, stress score marital status, occupation and family history of MI | NR          | LY, ICER, costs, the cumulative incidence of complications |
| DCEM [12] | Intensive Glycemic control and conventional treatment | Age, sex, ethnicity, hypertension status, hypercholesterolemia status and current smoking status | NR | 3% per-annual | LY, ICER, QALY, the number of discounted QALYS, costs the cumulative incidence of complications |
| Archimedes [19] | Three main types of treatments (1) Insulin; (2) Oral drugs; (3) Lifestyle (diet and exercise) | NR | NR | NR | LY, ICER, QALY, costs, the cumulative incidence of complications, expected |
| CDM [27] | Multiple interventions (1) Conventional therapy, (2) Intensive therapy | Age, sex, ethnicity, duration of diabetes, HbA1c, smoking, BP, BMI, Lipid levels, baseline complications | Age, BMI, HbA1c, SBP, T-CHOL, HDL, LDL, TRIG, smoking, alcohol consumption, duration of diabetes | NR          | LY, ICER, QALY, costs, the cumulative incidence of complications, an acceptability curve and/or NHB |
| UKPDS-OM1 [21] | (1) Conventional blood glucose control; (2) Intensive blood glucose control | Age, sex, ethnicity, HbA1c, BMI, smoking, BP, HDL age at diagnosis of diabetes, atrial fibrillation at diagnosis, PVD at diagnosis, history of diabetes related events, risk factors | HbA1c, SBP, HDL, smoking | NR          | LY, QALY, costs, the cumulative incidence of complications |
| Michigan [9] | (1) diet and exercise; (2) oral anti-diabetic; (3) insulin | Age, sex, ethnicity, HbA1c, BMI, smoking, SBP, age at diagnosis of diabetes, length of time in the current health, hypertension, serum total cholesterol level | NR | NR | Health utility scores, costs, the cumulative incidence of complications |
| Cardiff [10] | NR                          | Age, sex, ethnicity, smoking, duration of diabetes, risk factors | HbA1c, SBP, HDL, Weight, total cholesterol | 6% per-annum (costs) 1.5% per-annum (benefits) | QALY, cost, total number of clinical events |
| ODEM [11] | A multidisciplinary primary care diabetes management program | Age, sex, ethnicity, HbA1c, BMI, smoking, SBP, DBP, HDL, total cholesterol, age at diagnosis diabetes, medical history, history of other medical conditions | HbA1c, SBP, HDL, total cholesterol, smoking | 3% per-annual | LY, ICER, QALY, costs, the cumulative incidence of complications |
| Sheffield [22] | DESMOND intervention | Age, sex, ethnicity, HbA1c, BMI, smoking, SBP, HDL, total cholesterol, age at diagnosis of diabetes, therapy at entry | HbA1c, BP, lipid concentration, smoking | 3.5% per annum | LY, ICER, QALY, costs, CEAC, the cumulative incidence of complication |
| UKPDS-OM2 [28] | (1) Conventional blood glucose control; (2) Intensive blood glucose control; | Demographic factors (age, sex, BMI, ethnicity, duration of diabetes), risk factors, event history | HbA1c, SBP, HDL, LDL, eGFR, HR, PVD, smoking, WBC, atrial fibrillation, albuminuria, hemoglobin | NR          | LY, QALY, costs, annual incidence of death or complications |
Table 2 (continued)

| Model Name | Intervention and comparator (base case) | Basic data entered | Risk factors (base case) | Discounting | Model outcomes |
|------------|----------------------------------------|--------------------|--------------------------|-------------|----------------|
| ECHO [24]  | Anti-diabetes treatment                | Age, sex, HbA1c, BMI, SBP, HDL, duration of diabetes, history of pre-existing micro- and macro-vascular disease | Same with “basic data entered” | NR          | LY, ICER, QALY, costs, mean survival, NMBs |
| IHE [136]  | (1) Improved lifestyle patterns; (2) drug therapy | Age, sex, ethnicity, HbA1c, BMI, smoking, SBP, DBP, HDL, LDL, TC, WBC, HR, eGFR, duration of disease | Demographics (age, gender, ethnicity), biomarkers (HbA1c, SBP, DBP, TC, LDL, HDL, BMI, WBC, HR, eGFR), Pre-existing complications | NR          | LY, ICER, QALY, NMBs the cumulative incidence of complications |
| COMT [147] | Anti-diabetic therapy                  | Age, sex, ethnicity, HbA1c, HDL, smoking, BP, history of cardiovascular disease, medication history, SR, urine albumin/creatinine ratio | Age, sex, ethnicity, smoking, BMI, SBP, total/HDL cholesterol age at diagnosis diabetes, history of diabetes complications | 5% per-annual | LY, ICER, QALY, cost DALY, the cumulative incidence of complications |
| CDS [154]  | NR                                     | Age, sex, ethnicity, HbA1c, BMI, smoking, SBP, HDL, LDL, HR, hemoglobin, albuminuria, PVD, eGFR, WBC, the baseline complications, age at diagnosis diabetes | Age, sex, ethnicity, smoking, HbA1c, BMI, SBP, HR, LDL, HDL, hemoglobin, albuminuria, PVD, eGFR, WBC | NR          | LY, ICER, QALY, cost, the cumulative incidence of complications |

BMI Body Mass Index, BP blood pressure, CEAC cost-effectiveness acceptability curve, DBP diastolic blood pressure, DALY disability-adjusted life-year, eGFR estimated glomerular filtration rate, HR heart rate, HDL high-density lipoprotein, ICER incremental cost-effectiveness ratios, LY life year, LDL low-density lipoprotein cholesterol, MI myocardial infarction, NHB net health benefit, NMB(s) net monetary benefit(s), PVD peripheral vascular disease, QALY quality-adjusted life year, SBP systolic blood pressure, T-CHOL/TC total cholesterol, TRIG triglycerides, WBC white blood cell, NR not reported
| Model Name | CHD | Nephropathy | Retinopathy | Neuropathy |
|------------|-----|-------------|-------------|------------|
| NIDDM [20] | CVD (No CVD, CVD morbidity and mortality) | No nephropathy, MA 0.03–0.3 g/l (American Indians 30–299 mg/g Creatinine), proteinuria > 0.4 g/l ESRD | No retinopathy, non-proliferative retinopathy, PDR, significant ME, visual acuity < 20/100 in better eye | No neuropathy, symptomatic neuropathy, first LEA |
| DCEM [12] | Normal, CHD, angina, history of CA/MI, CA/MI, death | Normal, low micro/high micro, clinical nephropathy, ESRD, ESFR death | Normal, photocoagulation, blind | Normal, peripheral neuropathy LEA, history of LEA, subsequent LEA, LEA death |
| Anchimedes [19] | NA | NA | NA | NA |
| CDM [27] | MI (no history of MI, history of MI, death following MI), angina (no angina, history of angina), CHF (no CHF, history of CHF, death following CHF) | No renal complications, microalbuminuria, gross proteinuria, ESFR, death following ESFR | No retinopathy, BDR, PDR SVL, Macular edema (no macular edema, macular edema), cataract (no cataracts, first cataract with operation, second cataract with operation) | No neuropathy, neuropathy PVD(no PVD, PVD) |
| UKPDS-OM1 [21] | MI (non-fatal MI, fatal vascular cardiac event, sudden death), IHD, CHF | Creatinine levels of above 250 Snellen, 6/60 ETDRS log MAR 1.0, any acute inter-current illness, death due to renal failure | Blindness in one eye (a visual acuity of a digit or limb, fatal worse for any reason < persisting for > 3 months) | Amputation (first amputation# peripheral vascular event) |
| Michigan [9] | Normal, angina, MI/cardiac arrest, history of MI/cardiac arrest, death due to CVD | Normal, microalbuminuria, proteinauria, ESFR with dialysis ESFR and transplant, death due to ESFR | Normal, non-proliferative retinopathy, proliferative retinopathy, macular edema blindness | Normal, clinical neuropathy, amputation |
| Cardiff [10] | MI (non-fatal MI, fatal MI) | ESFR, MA, GPR subsequent years SVL/blindness | First year SVL/blindness, PVD (without amputation, with amputation) | Symptomatic neuropathy, LEA, |
| ODEM [11] | IHD (non-fatal IHD, fatal IHD), MI (non-fatal MI, fatal MI), heart failure (non-fatal, fatal failure) | Renal failure (fatal renal failure, non-fatal renal failure) | Blindness (non-fatal, fatal) | Amputation (non-fatal, fatal) |
| Sheffield [22] | CHD, heart failure | NR | NR | NR |
| UKPDS-OM2 [28] | MI (non-fatal MI, fatal MI, sudden death), IHD, CHF; second-event for MI, IHD, CHF | Same with the UKPDS-OM1 model nephropathy health state | Same with the UKPDS-OM1 model retinopathy health state | Same with the UKPDS-OM1 model neuropathy health state + second events for amputation |
| ECHO [24] | IHE, MI, CHF | No nephropathy, MA, GPR, ESFR | No retinopathy, BDR, PDR & blind, ME, ME & PDR & blindness, in 1 eye, blindness in both eyes | No neuropathy, symptomatic, PVD, symptomatic/PVD, foot ulcer, LEA, subsequent LEA |
| IHE [23] | MI (none, first MI, post-first MI, subsequent MIs), IHD (None, IHD), CHF (None, CHF) | None, Microalbuminuria, Macroumproteinuria, ESFR | None, BDR, PDR, ME, ME and PDR, SVL | None, PVD, LEA, Post LEA |
| COMT [26] | CHF, IHD, CVD, CVD death | ESFR | Blindness | Clinical neuropathy, amputation (minor, major) |
| CDS [25] | CHF, IHD, MI | Renal failure | Blindness | Amputation |

ASCVD: atherosclerotic cardiovascular disease, BDR: background diabetic retinopathy, CA: cardiac arrest, CHD: coronary heart disease, CHF: congestive heart failure, CVD: cardiovascular disease, ESRD: end-stage renal disease, GPR: gross proteinuria, IHD: ischemic heart disease, LEA: lower extremity amputation, MA: microalbuminuria, ME: macular edema, MI: myocardial infarction, PDR: proliferative retinopathy, PVD: peripheral vascular disease, SVL: severe visual loss, NA: not applicable, NR: not reported
| Model Name   | Stroke                                      | Foot ulcer                          | Others                                                                 | Adverse events                                               |
|-------------|---------------------------------------------|-------------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------|
| NIDDM [20]  | NR                                          | NR                                 | Mortality (CVD mortality, Non-CVD mortality)                          | NR                                                          |
| DCEM [12]   | Normal, stroke, history of Stroke, death    |                                     | Death (die from LEA, ESRD, CHD, stroke, or from other causes unrelated to diabetes) |                                                             |
| Archimedes 19 | NR                                          | NR                                 | The Archimedes model is a person-by-person, object-by-object simulation written in hundreds of differential equations that mathematically represent physiological pathways and the effects of multiple diseases, tests and treatments. No clear-cut health states available | Hypoglycemia                                                 |
| CDM [27]    | No history of stroke, history               | No foot ulcer, uninfected ulcer, healed ulcer, uninfected recurrent ulcer, infected recurrent ulcer, gangrene history of amputation | Non-specific mortality (alive and death)                              | Hypoglycemia (alive with hypoglycemia, death from hypoglycemia, lactic acidosis (alive with lactic acidosis, death from lactic acidosis) from lactic acidosis) |
| UKPDS- OM1 [21] | First non-fatal stroke, fatal stroke       | N                                  | Death (death in the first year with complications, death from causes unrelated to diabetes) | N                                                           |
| Michigan [9] | Normal, stroke, history of stroke death due to stroke | NR                                 | Mortality (die from ESRD, stroke CHD, non-renal & non-cardiovascular) |                                                               |
| Cardiff [10] | First non-fatal stroke, fatal stroke        | NR                                 | Death                                                                  | NR                                                          |
| ODEM [11]   | Fatal Stroke, non-fatal stroke              | NR                                 | Death                                                                  |                                                             |
| Sheffield [22] | Stroke (status not specified)               | NR                                 | Death (diabetes and other cause mortality)                             | Weight gain edema & reversible heart failure, hypos           |
| UKPDS- OM2 [28] | First non-fatal stroke, fatal stroke second events for stroke | Diabetic ulcer (Ulcer of the lower limb) | Same with the UKPDS-O1 model 'others' health state |                                                              |
| ECHO [24]   | Stroke                                      | Categorize it into neuropathy      | Mortality (event fatality, diabetes mortality, other mortality)        | Hypos (moderate, severe), other AEs (peripheral edema, Osteoporosis, Urinary tract disorders, vaginitis) |
| IHE [23]    | None, first stroke, post first stroke, subsequent strokes, post subsequent strokes | NR                                 | Mortality (event mortality, diabetes mortality and other mortality)    | Hypoglycemia (mild, moderate and severe), three user-specified grades of hypoglycemia and five other user-specified adverse events |
| COMT [26]   | Stroke                                      | Uncomplicated DFU, complicated DFU | Death                                                                  | Hypoglycemia                                                 |
| CDS [25]    | Stroke                                      | Foot ulcer                         | Mortality                                                              | NR                                                          |

**Table 4** Summary of model health states and adverse events

CHD coronary heart disease, CVD cardiovascular disease, DFU Diabetic foot ulcer, ESRD end-stage renal disease, LEA lower extremity amputation, NR not reported
Utility values for complications were obtained with the EQ-5D health status questionnaire [10, 21, 28] and the Quality of Well Being–Self-Administered questionnaire (QWB-SA) [9]. Most CUA were made by calculating QALYs. Some models [11, 12, 19, 20, 22–27] also took ICERs into account and thus could perform incremental analyses.

Main data sources for complications

All models reported some main data sources used to develop the health states of complications. The data commonly used to develop macrovascular complications included the Framingham datasets [20, 27] and the UKPDS [9, 10, 12, 19, 21–23, 27, 28]. For microvascular complications, the data sources were more complicated, and the commonly used sources were the Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) [20, 27] and the UKPDS [27]. More than half of the models applied multiple data sources for each complication, while the remaining models only contained one or two data resources (Table 6).

Model validation

Eleven of fourteen primary studies reported that one or more validation checks had been performed. Four studies [10, 24, 26, 28] presented model face validation, eleven studies [9, 10, 19–21, 23–28] presented internal validation, ten studies [10, 19–21, 23–28] presented external validation, while cross-validation was conducted by three studies [24, 25, 28]. However, none of the 14 studies demonstrated predictive validation. Primary studies using the DCEM, ODEM, and Sheffield models did not report aspects of model validation (Table 7).

Model uncertainty

Eleven models [9–12, 20–23, 25, 27, 28] were able to deal with model uncertainty, which was described in varying levels of detail in the primary studies. One-way sensitivity analysis was run in the Cardiff, DCEM, ODEM, and UKPDS-OM2 models. Based on 14 primary studies, none of the models reported a multi-way sensitivity analysis. Probabilistic sensitivity analysis (PSA) capabilities were reported by 9 models (NIDDM, DCEM, CDM, UKPDS-OM1/2, Michigan, Sheffield, IHE, COMT). Five models [9, 20, 25, 27, 28] used the Monte Carlo technique for PSA, while three models [12, 21, 27] used the nonparametric bootstrap method. Only 3 model [23, 27, 28] clearly indicated whether first-order or second-order uncertainty was performed (Table 8).

Model quality

In accordance with the checklist from Philips et al. [17], the percentage of fulfilled criteria was unequally distributed across studies and dimensions of quality (model structure, data, and consistency). Overall, 45% of the criteria were met, 26% were not met, and 29% were not applicable in the 14 primary studies. Figure 2 shows that on average across all included studies, model structure ranked the highest, with 65% of criteria for quality being met, followed by model...
Table 6  Summary of main data sources for diabetic complications

| Model Name | CHD | Nephropathy | Retinopathy | Neuropathy | Stroke | Others |
|------------|-----|-------------|-------------|------------|--------|--------|
| NIDDM [20] | The Framingham (CVD) [33] | WESDR [34], the Rochester Epidemiology Project [35] | WESDR [36, 37] | NHANES II [38], the Rochester Study (LEA) [39] | NR | NR |
| DCEM [12] | Weinstein MC et al. [40], Anderson KM et al. [41], Hunink MGM et al. [42] | NR | NR | NR | Mostly from UKPDS [21], Eastman et al. [40, 43] |
| Archimedes [19] | CVD: the Framingham [44] UKPDS [21], Herlitz et al. [45], the DIGAMI study [46] | ‘Features’ derived | WESDR [36, 48], EUORDIAB study [49] | Cataract: UKPDS [50] | | |
| CDM [27] | Wolfe RA et al. [47] | WESDR [36, 48] | Partenen et al. [51, 52] | | | |
| UKPDS-OM1 [21] | CHD:UKPDS [58], et al. [59], Ulvenstam G et al. [60], Lowel H et al. [61], Stevens RJ et al. [62] | Malmberg K Gall MA et al. [63], Ballard DJ et al. [35], Ravid M M et al. [64] | Klein R et al. [37, 65, 66], Moss SE et al. [67, 68] | Sands ML et al. [69], Adler AI et al. [70] | UKPDS [58], Hier DB et al. [71], Sacco RL et al. [72], Kathari V et al. [73] |
| Michigan [9] | Cholesterol: UKPDS [58], et al. [59], Ulvenstam G et al. [60], Lowel H et al. [61], Stevens RJ et al. [62] | Malmberg K Gall MA et al. [63], Ballard DJ et al. [35], Ravid M M et al. [64] | Klein R et al. [37, 65, 66], Moss SE et al. [67, 68] | Sands ML et al. [69], Adler AI et al. [70] | UKPDS [58], Hier DB et al. [71], Sacco RL et al. [72], Kathari V et al. [73] |
| Cardiff [10] | Cholesterol: UKPDS [58], et al. [59], Ulvenstam G et al. [60], Lowel H et al. [61], Stevens RJ et al. [62] | Malmberg K Gall MA et al. [63], Ballard DJ et al. [35], Ravid M M et al. [64] | Klein R et al. [37, 65, 66], Moss SE et al. [67, 68] | Sands ML et al. [69], Adler AI et al. [70] | UKPDS [58], Hier DB et al. [71], Sacco RL et al. [72], Kathari V et al. [73] |
| ODEM [11] | Cholesterol: UKPDS [58], et al. [59], Ulvenstam G et al. [60], Lowel H et al. [61], Stevens RJ et al. [62] | Malmberg K Gall MA et al. [63], Ballard DJ et al. [35], Ravid M M et al. [64] | Klein R et al. [37, 65, 66], Moss SE et al. [67, 68] | Sands ML et al. [69], Adler AI et al. [70] | UKPDS [58], Hier DB et al. [71], Sacco RL et al. [72], Kathari V et al. [73] |
| Sheffield [22] | UKPDS [62] | DCCT[76] | NR | NR | UKPDS [73] |
| UKPDS-OM2 [28] | UKPDS [62] | DCCT[76] | NR | NR | UKPDS [73] |
| ECHO [24] | UKPDS [21] | Eastman et al. [43] | Eastman et al. [43] | Eastman et al. [43], Bagust et al. [77] | UKPDS [21] |
| IHE [23] | Macravascular: NDR [78], UKPDS [21, 28] | Bagust A et al. [77] | Bagust A et al. [79] | Eastman R C et al. [20] | NR |
| COMT [26] | Gerstein HC et al. [80] Wing RR et al. [81] | NR | NR | NR | Perreault L et al. [82] |
| CDS [25] | Mostly from ADVANCE [83], LDS [84], THIN85 |

NR not reported
consistency (43%) and model data (32%) (Tables 9, 10, and 11).

Discussion

Our systematic review included 140 studies describing 14 decision models in T2DM. We extracted data from the primary studies for each model, and the remaining 126 studies were identified as secondary studies (Supplementary material Appendix 2). We found that there were fairly mature modeling technologies and relatively fixed model structures for existing decision models for T2DM. Overall, the 13 identified models (except for the Archimedes model) divided the disease into discrete health states, followed by establishing Markov chains or risk equations to simulate the lifelong course of the disease. However, the review of these studies showed that the existing T2DM

| Table 7 | Summary of model validation (data only extracted from 14 primary citations: for baseline cases) |
|---------|--------------------------------------------------------------------------------------------------|
| Model   | Face validation | Internal validation | External validation | Cross-validation | Predictive validation |
| Name    |              |                     |                     |                  |
| NIDDM [20] | √            | √                   |                     |                  |
| DCEM [12] | NR           | NR                  | NR                  | NR               | NR                  |
| Archimedes [19] | √               | √                   |                     |                  |
| CDM [27] | √            | √                   |                     |                  |
| Michigan [9] | √              | √                   |                     |                  |
| Cardiff [10] | √              | √                   |                     |                  |
| ODEM [11] | NR           | NR                  | NR                  | NR               | NR                  |
| Sheffield [151] | NR              | NR                  | NR                  | NR               | NR                  |
| UKPDS-OM2 [28] | √              | √                   | √                   | √                |
| ECHO [24] | √            | √                   | √                   | √                |
| IHE [23] | √            | √                   |                     |                  |
| COMT [26] | √            | √                   | √                   | √                |
| CDS [25] | √            | √                   | √                   | √                |

NR not reported (for baseline cases)

| Table 8 | Summary of model uncertainty (data only extracted from 14 primary citations: for baseline cases) |
|---------|--------------------------------------------------------------------------------------------------|
| Model   | One-way sensitivity analysis | Multi-way sensitivity analysis | Probabilistic sensitivity analysis (PSA) |
| Name    |                                |                                |                                       |
| NIDDM [20] | √ Use Monte Carlo simulations              |                                |                                       |
| CDC-RTI [12] | √ The nonparametric bootstrap method is used        |                                |                                       |
| Archimedes [19] | NR                  | NR                  | NR                  |
| CDM [27] | √ The nonparametric bootstrap method is used + first and second-order Monte Carlo simulations |                                |                                       |
| UKPDS-OM1 [21] | √ A combination of bootstrap methods and multiple imputation methods were used                 | Use Monte Carlo simulations    |                                       |
| Michigan [9] | √ Use Monte Carlo simulations             |                                |                                       |
| Cardiff [10] | √ Use Monte Carlo simulations               |                                |                                       |
| ODEM [11] | √                                        |                                |                                       |
| Sheffield [22] |                                |                                |                                       |
| UKPDS-OM2 [28] | √ Use Monte Carlo or first order uncertainty + Parameter or second order uncertainty |                                |                                       |
| ECHO [24] | √ Use Monte Carlo simulations               |                                |                                       |
| IHE [23] | √ Second order PSA                          |                                |                                       |
| COMT [26] | √                                        |                                |                                       |
| CDS [25] | √ Use Monte Carlo simulations               |                                |                                       |

NR not reported (for baseline cases)
models still had certain limitations in terms of quality and extrapolation.

Previous systematic reviews of T2DM models [29–32] have focused more on model outputs than on their capabilities. However, the primary focus of this systematic review was the capabilities of these models. Based on the characteristics of each model, we briefly summarized the more suitable models for different study demands as follows:

1. If a study focused on simulating the trajectory of T2DM and/or diabetic macrovascular complications (e.g., cardiovascular disease, angina, myocardial infarction, or cardiac arrest), the best choice is the DCEM model.

2. If the study focused on simulating the trajectory of T2DM and/or diabetic microvascular complications (e.g., retinopathy and/or nephropathy), the best choices are the NIDDM model or the Michigan model. It is worth noting that the NIDDM model was the first diabetes model and it is rarely used now, but it is still of great value in the development of diabetes models. Many current models were constructed based on the NIDDM model.

Table 9 Philips checklist results

![Philips checklist results](image_url)
If the objective is to conduct a comprehensive study of the trajectory of T2DM and its various complications, the best choices are the CDM model, the UKPDS OM1/2 model, the IHE model, the ODEM model, the Cardiff model, the Sheffield model, CDS model, COMT model, or the ECHO model.

If the objective is to simulate a continuous trajectory of diabetes and its complications, the Archimedes model is the best choice.

If the study is aimed at Chinese and Asian populations, it is recommended to use the COMT model.

### Table 10 Philips checklist results

| Data | 
| --- | 
| Data identification methods transparent and appropriate? | 
| Choices between data sources justified appropriately? | 
| Attention paid to identifying data for important parameters? | 
| Systematic methods used to identify the most appropriate data? | 
| Quality of the data been assessed appropriately? | 
| Where expert opinion has been used, are methods described? | 
| Modelling methods based on justifiable techniques? | 
| Choice of baseline data described and justified? | 
| Transition probabilities calculated appropriately? | 
| Half-cycle correction applied to both cost and outcome? | 
| If not, has this omission been justified? | 
| Treatment effects from trial data synthesised appropriately? | 
| Extrapolation of short term results documented and justified? | 
| Alternative assumptions explored through sensitivity analysis? | 
| Continuing treatment effect assumptions documented and justified? | 
| Costs incorporated into the model justified? | 
| Source for all costs been described? | 
| Discount rates described and justified? | 
| Utilities incorporated into the model appropriate? | 
| Source for the utility weights referenced? | 
| Methods of derivation for the utility weights justified? | 
| Data incorporated into the model described and referenced? | 
| Use of mutually inconsistent data been justified? | 
| Process of data incorporation transparent? | 
| Choice of distribution for each parameter described and justified? | 
| Second order uncertainty reflected for data incorporated as distributions? | 
| Four principal types of uncertainty been addressed? | 
| If not, has omission of particular forms of uncertainty been justified? | 
| Methodological uncertainties been tested? | 
| Structural uncertainties have been addressed via sensitivity analysis? | 
| Heterogeneity dealt with by testing different subgroups? | 
| Methods of assessment of parameter uncertainty appropriate? | 
| Data incorporated as point estimates ranges tested stated clearly? | 

### Table 11 Philips checklist results

| Consistency | 
| --- | 
| Mathematical logic of model tested before use? | 
| Conclusions valid given the data presented? | 
| Counterintuitive results from the model explained and justified? | 
| If model calibrated against independent data, differences explained? | 
| Result compared with previous models and differences explained? |
In this systematic review, the 14 identified models were rather heterogeneous in terms of model structures, the main data sources used by models, and model uncertainty. We observed that most model structures were composed of discrete health states, and each discrete state was simulated annually through transition probabilities. However, the Archimedes model applied a comprehensive approach to model structure by simulating the disease at the organ level; it has no clear-cut health states. The level of detail in the classification of health states was different between models, and not all models had a clear definition of each health state it contained. However, the desired level of complexity must be balanced with the required transparency. Despite variations in model structure and scope, there should be a reasonably clear consensus of what broad categories of health states should be considered in the same type of T2DM models.

Many of the data sources used in model development are older data sets, such as the UKPDS and Framingham data sets; this limitation also exists in T1DM models. Although this limitation is well known, these data sources are currently recognized as the best available sources for modeling. This review also found that most of the data inputted to models were based on European populations; only 1 of the 14 models was developed based on Asian population data (the COMT model). However, in the era of real-world evidence, with an increasing availability of registry data from clinical practice settings, model validation incorporating modern T2DM epidemiological data into disease progression equations for simulation will be important. The development of this technology may resolve the impacts of limitations on model simulation. The level of description of model uncertainty varied among the included studies, and there is a lack of standardized terminology regarding model uncertainty in these studies. This may hinder the understanding of what has actually been carried out. For example, in studies conducting Monte Carlo simulation or PSA, it was not always clear whether the report considered first- or second-order uncertainty. This should be noted because many health technology assessment (HTA) agencies demand that second-order uncertainty be captured in PSA. However, it does require multiple and complex computer calculations to solve second-order uncertainty through the PSA of the microsimulation models. This may be why some studies have not clearly stated their uncertainty. Although a rigorous systematic review was undertaken to identify all relevant studies of decision models in T2DM, some limitations of this review should be acknowledged. First, the data were extracted mainly through the primary study for each model, rather than the latest study, which may cause some of the latest views on models to be ignored. In general, ICERs were also obtained when calculating QALYs to perform CUA. However, in model outcomes, 13 models reported QALYs, and only 10 of these models reported ICERs. This may be due to the lack of data from secondary studies. A similar review should be conducted on secondary studies of each model to provide a more comprehensive evaluation of the included models. Second, models with a limited focus on particular sub-components of T2DM were excluded. Models focused on particular sub-components of T2DM may provide a more meticulous and complex simulation method. However, these models only involved specific components of T2DM, which may lead to failure to consider the connection of the various components of diabetes in modeling. Finally, the assessment of study quality may be biased, as some studies were not described in full detail because of word limits for publications.

**Conclusion**

We conducted a comprehensive systematic review focusing on capabilities of the existing decision models for T2DM, and briefly summarized the more suitable models for different study demands. It is necessary to use decision models to simulate the lifelong course of diseases, especially for chronic diseases, to evaluate whether new technologies or interventions have values. A general conclusion from the review is that the existing decision models for T2DM were rather heterogeneous on the level of detail in the classification of health states. Thus, more attention should be focused on balancing the desired level of complexity against the required level of transparency in the development of T2DM decision models. Furthermore, we should consider including secondary studies for a more comprehensive systematic review.

**Registration**

This systematic review was registered in the PROSPERO database (CRD42020171838). https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020171838

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00592-021-01742-6.

**Acknowledgements** This work was sponsored by National Key R&D Program of China (No. 2018YFC1311502), and Gansu Province Health Industry Research Project (No. GWSKY2020-08). The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

**Author contributions** All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Jiayu Li, Yun Bao and Xuedi Chen. Jiayu Li and Yun Bao contributed equally to this work. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Funding This work was sponsored by National Key R&D Program of China (No. 2018YFC1311502), and Gansu Province Health Industry Research Project (No. GSWSKY2020-08). The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

Availability of data and material Evaluated studies are publicly available peer-reviewed scientific publications.

Declarations

Conflict of interest The authors declare that they have no conflicts of interest.

Human and Animal Rights disclosure This article does not contain any studies with human or animal subjects performed by the any of the authors.

Informed consent No identifying information from individual patients was retrieved or published at any stage by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. International Diabetes Federation (2019) IDF Diabetes Atlas. 9th ed. Brussels: International Diabetes Federation; 2019. Available at http://www.diabetesatlas.org. Accessed Feb 2020
2. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017). Lancet 390(10100):1260–1344. https://doi.org/10.1016/s0140-6736(17)32130-x
3. Wang L, Gao P, Zhang M et al (2017) Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317(24):2515–2523. https://doi.org/10.1001/jama.2017.7596
4. Chan JC, Zhang Y, Ning G (2014) Diabetes in China: a societal solution for a personal challenge. Lancet Diabetes Endocrinol 2(12):969–979. https://doi.org/10.1016/s2213-8587(14)70144-5
5. Xu Y, Wang L, He J et al (2013) Prevalence and control of diabetes in Chinese adults. JAMA 310(9):948–959. https://doi.org/10.1001/jama.2013.168118
6. Dakin HA, Devlin NJ, Odeyemi IA (2006) “Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making. Health Policy 77(3):352–367. https://doi.org/10.1016/j.healthpol.2005.08.008
7. Caro JJ, Briggs AH, Siebert U, Kuntz KM (2012) Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—1. Value Health 15(6):796–803. https://doi.org/10.1016/j.jval.2012.06.012
8. Weinstein MC, O’Brien B, Hornberger J et al (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6(1):9–17. https://doi.org/10.1046/j.1524-4733.2003.00234.x
9. Zhou H, Isaman DJM, Messinger S et al (2005) A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 28(12):2856–2863. https://doi.org/10.2337/diabetes.28.12.2856
10. McEwan P, Peters JR, Bergennheim K, Currie CJ (2006) Evaluation of the costs and outcomes from change in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecastcer). Curr Med Res Opin 22(1):121–129. https://doi.org/10.1185/030079906X80350
11. O’Reilly D, Hopkins R, Blackhouse G et al (2007) Long-term cost-utility analysis of a multidisciplinary primary care diabetes management program in Ontario. Can J Diabetes 31(3):205–214. https://doi.org/10.1016/S1499-2671(07)33007-0
12. Hoerger TJ, Bethke AD, Richter A et al (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. J Am Med Assoc 287(19):2542–2551
13. Kahn R (2004) Guidelines for computer modeling of diabetes and its complications. Diabetes Care 27(9):2262–2265. https://doi.org/10.2337/diacare.27.9.2262
14. Leal J, Morrow LM, Khurshid W, Pagano E, Feenstra T (2019) Decision models of prediabetes populations: a systematic review. Diabetes Obes Metab 21(7):1558–1569. https://doi.org/10.1111/dom.13684
15. Henriksson M, Jindal R, Sternhufvud C et al (2016) A systematic review of cost-effectiveness models in type 1 diabetes mellitus. Pharmaco economics 34(6):569–585. https://doi.org/10.1007/s40273-015-0374-8
16. Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med 18(3):e1003583. https://doi.org/10.1371/journal.pmed.1003583
17. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S (2006) Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmaco economics 24(4):355–371. https://doi.org/10.2165/00019053-200624040-00006
18. Wright D, Little R, Turner D, Thornley T (2019) Diabetes screening through community pharmacies in England: A cost-effectiveness study. Pharm (Basel). https://doi.org/10.3390/pharmacy7010030
19. Eddy DM, Schlessinger L (2003) Archimedes: a trial-validated model of type 2 diabetes. Diabetes Care 26(11):3093–3101. https://doi.org/10.2337/diacare.26.11.3093
20. Eastman RC, Javitt JC, Herman WH et al (1997) Model of complications of NIDDM I Model construction and assumptions. Diabetes Care 20(5):725–734. https://doi.org/10.2337/diacare.20.5.725
21. Clarke PM, Gray AM, Briggs A et al (2004) A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) outcomes model (UKPDS No. 68). Diabetologia 47(10):1747–1759. https://doi.org/10.1007/s00125-004-1527-z
22. Gillett M, Dallosso HM, Dixon S et al (2010) Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: Cost effectiveness analysis. BMJ. https://doi.org/10.1136/bmj.c4093
23. Lundqvist A, Carlsson KS, Johansen P, Andersson E, Willis M (2014) Validation of the IHE cohort model of type 2 diabetes
and the impact of choice of macrovascular risk equations. PLoS ONE. https://doi.org/10.1371/journal.pone.0110235

24. Willis M, Asseburg C, He J (2013) Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ 16(8):1007–1021. https://doi.org/10.1080/13696998.2013.809352

25. Su ZT, Bartelt-Hofer J, Brown S et al (2019) The use of computer simulation modeling to estimate complications in patients with type 2 diabetes mellitus: comparative validation of the cornerstone diabetes simulation model. Pharmacoecon Open. https://doi.org/10.1007/s41699-019-0156-x

26. Wu B, Ma J, Zhang S, Zhou L, Wu H (2018) Development and validation of a health policy model of type 2 diabetes in Chinese setting. J Comparative Effect Res. https://doi.org/10.2217/ cer-2018-0001

27. Palmer AJ, Roze S, Valentine WJ et al (2004) The CORE Diabetes model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 20(Suppl 1):S5-26. https://doi.org/10.1185/030079904x1980

28. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM (2013) UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom prospective diabetes study. UKPDS 82. Diabetologia 56(9):1925–1933. https://doi.org/10.1007/s00125-013-2940-y

29. Asche CV, Hippler SE, Earich DT (2014) Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. Pharmacoeconomics 32(1):15–27. https://doi.org/10.1007/s40273-013-0117-7

30. Becker C, Langer A, Leidl R (2011) The quality of three decision-analytic diabetes models: a systematic health economic assessment. Expert Rev Pharmacoecon Outcomes Res 11(6):751–762. https://doi.org/10.1586/erp.11.68

31. Yi Y, Philips Z, Bergman B, Burslem K, (2013) Economic models in type 2 diabetes. Curr Med Res Opin 26(9):2105–2118. https://doi.org/10.1185/030079905.2010.494451

32. Tarride JE, Hopkins R, Blackhouse G et al (2010) A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 28(4):255–277. https://doi.org/10.1007/s40273-013-0117-7

33. Lerner DJ, Kannel WB (1986) Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111(2):383–390. https://doi.org/10.1016/0002-8703(86)90155-9

34. Klein R, Klein BE, Moss SE (1993) Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care 16(10):1325–1330. https://doi.org/10.2337/diacare.16.10.1325

35. Ballard DJ, Humphrey LL, Melton LJ 3rd et al (1988) Epidemiology of persistent proteinuria in type II diabetes mellitus Population-based study in Rochester Minnesota. Diabetes 37(4):405–412. https://doi.org/10.2337/db87-0405

36. Javitt JC, Aiello LP, Chiang Y et al (1994) Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 17(8):909–917. https://doi.org/10.2337/diacare.17.8.909

37. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1989) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 107(2):244–249. https://doi.org/10.1001/archoph.1989.01070 010250031

38. Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU (1998) Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Diabetes Care 21(4):530–534. https://doi.org/10.2337/diacare.21.4.530

39. Dyck PJ, Kratz KM, Karnes JL et al (1993) The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43(4):817–824. https://doi.org/10.1212/wnl.43.4.817

40. Weinstein MC, Coxson PG, Williams LW et al (1987) Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 77(11):1417–1426. https://doi.org/10.2105/ajph.77.11.1417

41. Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121(1 Pt 2):293–298. https://doi.org/10.1016/0002-8703(91)90861-b

42. Hunink MG, Goldman L, Tosteson AN et al (1997) The recent decline in mortality from coronary heart disease, 1980–1990. The effect of secular trends in risk factors and treatment. JAMA 277(7):535–542

43. Eastman RC, Javitt JC, Herman WH et al (1997) Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20(5):735–744

44. D’Agostino RB, Russell MW, Huse DM et al (2000) Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 139(2 Pt 1):272–281. https://doi.org/10.1067/mhj.2000.96469

45. Herlitz J, Bång A, Karlson BW (1996) Mortality, place and mode of death and reinfarction during a period of 5 years after acute myocardial infarction in diabetic and non-diabetic patients. Cardiology 87(5):423–428. https://doi.org/10.1159/000177131

46. Almbrand B, Johannesson M, Sjöstrand B, Malmberg K, Rydén L (2000) Cost-effectiveness of intensive insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J 21(9):733–739. https://doi.org/10.1053/euhj.1999.1859

47. Wolfe RA, Ashby VB, Milford EL et al (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341(23):1725–1730. https://doi.org/10.1056/nejm19991202341203

48. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1989) The Wisconsin epidemiologic study of diabetic retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107(2):237–243. https://doi.org/10.1001/archoph.1989.01070010243030

49. Chaturvedi N, Sjolie AK, Stephenson JM et al (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351(9095):28–31. https://doi.org/10.1016/S0140-6736(97)60209-0

50. Stratton IM, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 44(2):156–163. https://doi.org/10.1007/s001250051594

51. Partanen J, Niskanen L, Lehtinen J et al (1995) Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333(2):89–94. https://doi.org/10.1056/nejm19950713333203

52. The effect of intensive diabetes therapy on the development and progression of neuropathy The Diabetes Control and Complications Trial Research Group (1995). Ann Intern Med 122(8):561–568. https://doi.org/10.7326/0003-4819-122-8-199504150-00001

53. Petty GW, Brown RD Jr, Whisnant JP et al (1998) Survival and recurrence after first cerebral infarction: a population-based
study in Rochester, Minnesota, 1975 through 1989. Neurology 50(1):208–216. https://doi.org/10.1212/wnl.50.1.208
54. Sprafka JM, Vornig BA, Shahar E, McGovern PG (1994) Trends in diabetes prevalence among stroke patients and the effect of diabetes on stroke survival: the Minnesota Heart Survey. Diabet Med 11(7):678–684. https://doi.org/10.1111/j.1464-5491.1994.tb00332.x
55. Ragnarson Tennvall G, Apelqvist J (2001) Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia 44(11):2077–2087. https://doi.org/10.1007/s001250100603
56. Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y (1999) Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 159(3):281–284. https://doi.org/10.1001/archinte.159.3.281
57. Stepka M, Rogala H, Czyzak A (1993) Hypoglycemia: a major problem in the management of diabetes in the elderly. Aging (Milano) 5(2):117–121. https://doi.org/10.1007/bf03324137
58. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group (1998). Lancet 352(9131):837–853
59. Malmberg K, Yusuf S, Gerstein HC et al (2000) Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102(9):1014–1019. https://doi.org/10.1161/01.cir.102.9.1014
60. Ulvenstam G, Aberg A, Bergstrand R et al (1989) Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 34(8):787–792. https://doi.org/10.2337/diab.34.8.787
61. Löwel H, Koenig W, Engel S, Hörmann A, Keil U (2000) The San Luis valley diabetes study. Diabetes Care 23(3):322–329. https://doi.org/10.2337/diacare.23.3.322
62. Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101(6):671–679
63. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH (1997) Risk factors for development of incipient and overt diabetic neuropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314(7083):783–788. https://doi.org/10.1136/bmj.314.7083.783
64. Ravid M, Savin H, Jutrin I et al (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118(8):577–581. https://doi.org/10.7326/0003-4819-118-8-19930415-00001
65. Klein R, Klein BE, Cruickshanks KJ (1994) The Wisconsin Epidemiologic Study of diabetic retinopathy XIV Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 112(9):1217–1228. https://doi.org/10.1001/archophthalm.1994.010902010105023
66. Klein R, Klein BE, Cruickshanks KJ (1995) The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102(1):7–16. https://doi.org/10.1016/s0161-6420(95)31052-4
67. Moss SE, Klein R, Klein BE (1988) The incidence of vision loss in a diabetic population. Ophthalmology 95(10):1340–1348. https://doi.org/10.1016/s0161-6420(88)32991-x
68. Moss SE, Klein R, Klein BE (1994) Ten-year incidence of visual loss in a diabetic population. Ophthalmology 101(6):1061–1070. https://doi.org/10.1016/s0161-6420(94)31217-6
69. Sands ML, Shetterly SM, Franklin GM, Hamman RF (1997) Incidence of distal symmetric (sensory) neuropathy in NIDDM. The Diabetes Control and Complications (DCCT) Research Group (1995). Kidney Int 44(12):2140–2155. https://doi.org/10.1007/s004220000023
70. Bagust A, Hopkinson PK, Maier W, Currie CJ (2001) An economic model of the long-term health care burden of type II diabetes. Diabetologia 44(12):2140–2155. https://doi.org/10.1007/s001250000023
71. Ahmad KI, Miller ME, Genuth S et al (2008) Intensive blood-glucose control and vascular outcomes in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group (1998). Lancet 352(9131):837–853
72. Perreault L, Pan Q, Mather KJ et al (2012) Effect of regression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group (1995). Kidney Int 47(6):1703–1720. https://doi.org/10.1038/ki.1995.236
73. Clarke PM, Simon J, Cull CA, Holman RR (2006) Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36. Diabetes Care 29(7):1506–1511. https://doi.org/10.2337/diacare.29.7.1506
practice data in the UK. Pharmacoeconomics 33(2):149–161. https://doi.org/10.1007/s40273-014-0225-z
86. Diabetes Control and Complications Trial Research Group (1995)
The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 113(1):36–51. https://doi.org/10.1001/archopht.1995.01100010038019

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.